华康生物医学2024年报

(incorporated in the Cayman Islands with limited liability)Stock Code: 8622 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OFHONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM GEM has been positioned as a market designed to accommodate small and mid-sized companiesto which a higher investment risk may be attached than other companies listed on the StockExchange. Prospective investors should be aware of the potential risks of investing in suchcompanies and should make the decision to invest only after due and careful consideration. Given that the companies listed on GEM are generally small and mid-sized companies, there isarisk that securities traded on GEM may be more susceptible to high market volatility thansecurities traded on the Main Board of the Stock Exchange and no assurance is given that therewill be a liquid market in the securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for thecontents of this report (“Report”), make no representation as to its accuracy or completeness andexpressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon thewhole or any part of the contents of the Report. This Report, for which the directors (the “Directors”) of Huakang Biomedical Holdings Company Limited(the “Company”, and together with its subsidiaries, the “Group”, “we” or “our”) collectively andindividually accept full responsibility, includes particulars given in compliance with the Rules Governing theListing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of givinginformation with regard to the Group. The Directors, having made all reasonable enquiries, confirm that tothe best of their knowledge and belief, the information contained in this Report is accurate and completein all material respects and not misleading or deceptive, and there are no other matters the omission ofwhich would make any statement herein or this Report misleading. GEM GEMGEMGEM GEMGEM CONTENTSCONTENTS Corporate Information3Chairman’s Statement5Management Discussion and Analysis7Biographies of Directors andSenior Management21Corporate Governance Report31Environmental, Social andGovernance Report58Report of the Directors95Independent Auditor’s Report115Consolidated Statement ofProfit or Loss andOther Comprehensive Income126Consolidated Statement ofFinancial Position127Consolidated Statement ofChanges in Equity129Consolidated Statement ofCash Flows131Notes to the ConsolidatedFinancial Statements133Financial Summary248 CORPORATE INFORMATION Ms. Shih Mei Ling(appointed on 3 December2024 and resigned on28 February 2025)Mr. Tsui Wing Tak(appointed on 22 January2025) Board of Directors Remuneration Committee Executive Directors Dr. Cheng Faat Ting Gary(Chairman)Dr. Chow Kwok Fai JosephMr. Zhang Chunguang Mr. Zhang Shuguang(Chairman)Mr. Zhang ChunguangMr. Poon Lai Yin MichaelMr. He Jiaming Nomination Committee Non-executive Directors Mr. Zhang Shuguang(Chairman)Dr. Chow Kwok Fai JosephMr. Chan Kin Sang(resigned on 2 April 2024)Ms. Chow Ching Man(resigned on 22 January 2025)Mr. Tsui Wing Tak(appointed on 22 January2025) Dr. Bu Su(appointed on 8 August 2024)Dr. Xu Ming(appointed on 25 October2024) Audit Committee Dr. Cheng Faat Ting Gary(Chairman)Dr. Chow Kwok Fai JosephMr. Chan Kin Sang(resigned on 2 April 2024)Ms. Chow Ching Man(resigned on 22 January 2025)Mr. Tsui Wing Tak(appointed on 22 January2025) Independent Non-executiveDirectors Dr. Chow Kwok Fai JosephDr. Cheng Faat Ting GaryMr. Chan Kin Sang(resigned on 2 April 2024)Ms. Chow Ching Man(resigned on 22 January 2025) Company Secretary Mr. Chau Lai Ki CORPORATE INFORMATION Principal Place of Businessin Hong Kong Principal Share Registrarand Transfer Office in theCayman Islands Authorised Representatives(for the purposes of theGEM Listing Rules)GEM Room 04, 9 Floor,Kimberley House,35–35A Kimberley Road,Tsim Sha Tsui,Kowloon,Hong Kong35–35A904 Conyers Trust Company(Cayman) LimitedCricket Square,Hutchins Drive,P.O. Box 2681,Grand Cayman KY1-1111,Cayman Islands Mr. Zhang ShuguangMr. Poon Lai Yin Michael Compliance OfficerMr. Poon Lai Yin Michael Hong Kong ShareRegistrar and TransferBranch Office Principal Place of Businessin the PRC Legal Advisers as toHong Kong laws Tricor Investor Services Limited17/F, Far East Financial Centre,16 Harcourt Road,Hong Kong1617 1–3/F and 5/F, Building D,Shenzhen Junxuan,No. 16 Yinkui Road,Kui Xin Community,Kui Chong Office,Dapeng New District,Shenzhen,The PRC16D Tung, Ng, Tse & LamSolicitors Auditor Forvis Mazars CPA Limited Company’s Websiteshttp://www.huakangbiomedical.com Registered Office Stock Code8622 Cricket Square,Hutchins Drive,P.O. Box 2681,Grand Cayman, KY1-1111Cayman Islands CHAIRMAN’S STATEMENT Dear Shareholders, On behalf of the board of directors (the “Board”) ofHuakang Biomedical Holdings Company Limited, I ampleased to present the Group’s annual results for the yearended 3